Latest Breaking News On - Katja margell - Page 4 : comparemela.com

Hansa Biopharma and German payer head association agree on reimbursement price for Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients

/PRNewswire/ Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological conditions, today announces.

Hansa biopharmaPrnewswire hansa biopharmaKlaus sindahlKatja margellNational association of statutory health insurance fundsEuropean unionEuropean medicines agencyEuropean medicines agency ema priorityHead of corporate communicationsNational associationStatutory health insurance fundsNasdaq stockholmMedicines market reorganization actHuman leukocyte antigensEuropean marketing authorizationEnd stage renal disease

Hansa Biopharma and German payer head association agree on reimbursement price for Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients

/PRNewswire/ Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological conditions, today announces.

Hansa biopharmaPrnewswire hansa biopharmaKlaus sindahlKatja margellNational association of statutory health insurance fundsEuropean unionEuropean medicines agencyEuropean medicines agency ema priorityHead of corporate communicationsNational associationStatutory health insurance fundsNasdaq stockholmMedicines market reorganization actHuman leukocyte antigensEuropean marketing authorizationEnd stage renal disease

Hansa Biopharma and German payer head association agree on reimbursement price for Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients

Hansa Biopharma and German payer head association agree on reimbursement price for Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
di.se - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from di.se Daily Mail and Mail on Sunday newspapers.

Hansa biopharmaKlaus sindahlKatja margellNational association of statutory health insurance fundsEuropean unionEuropean medicines agencyEuropean medicines agency ema priorityHead of corporate communicationsNational associationStatutory health insurance fundsNasdaq stockholmMedicines market reorganization actHuman leukocyte antigensEuropean marketing authorizationEnd stage renal diseaseProduct characteristicsfound

Hansa Biopharma announces positive early access decision by French Haute Autorité de Santé to use Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients

/PRNewswire/ Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological conditions, today announces that.

United kingdomHansa biopharmaKlaus sindahlKatja margellTransparency commissionNational security systemEuropean unionEuropean medicines agencyEuropean medicines agency ema priorityA health technology assessmentFrench public health codeHead of corporate communicationsNasdaq stockholmHaute autoritMarketing authorizationAgence de biom

Hansa Biopharma announces positive early access decision by French Haute Autorité de Santé to use Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients

/PRNewswire/ Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological conditions, today announces that.

United kingdomHansa biopharmaKlaus sindahlKatja margellTransparency commissionNational security systemEuropean unionEuropean medicines agencyEuropean medicines agency ema priorityA health technology assessmentFrench public health codeHead of corporate communicationsNasdaq stockholmHaute autoritMarketing authorizationAgence de biom